DoD Fought Wuxi Apptec Challenge to Military List
The Department of Defense’s filing sustains the 1260H listing for a firm whose access to U.S. contracts hangs in the balance.
Updated on Sept. 22, 2026 in Healthcare
Live Poll
Do you trust the federal government's current process for blacklisting foreign companies as military threats?
The Department of Defense has contested Wuxi Apptec’s lawsuit challenging its inclusion on the 1260H list of Chinese military companies. The firm is seeking to avoid classification as a biotechnology company of concern under the upcoming Biosecure Act.
Why it matters
A final designation as a 1260H entity would effectively bar Wuxi Apptec from U.S. government contracts, creating significant supply chain uncertainty for healthcare providers and researchers relying on the firm's services.
The Department of Defense maintains the 1260H designation despite a preliminary injunction issued in August 2026. The firm’s legal effort aims to prevent its inclusion on the initial Biosecure biotechnology list due this December.
The players
Wuxi Apptec
A global biotechnology firm providing research and manufacturing services to the pharmaceutical and healthcare sectors.
Department of Defense
The executive department responsible for federal military policy and maintaining the 1260H list of Chinese military companies.
The details
The Department of Defense filed a formal response in the U.S. District Court for the District of Columbia arguing that its listing of the firm was justified. Wuxi Apptec previously secured a temporary reprieve from the court after claiming the listing was arbitrary. Litigation will now proceed to discovery to determine if the company meets the criteria for military affiliation.
Timeline
June 2026: Wuxi Apptec received its 1260H military company designation.
August 2026: A federal court granted the firm a temporary reprieve from the list.
September 18, 2026: The Department of Defense filed its response to the legal complaint.
December 2026: The deadline approaches for the initial Biosecure list of companies of concern.
Market Landscape
This case marks a significant point of friction between international biotechnology suppliers and the federal government following the passage of the Biosecure Act. It illustrates the growing risk that national security designations will dictate procurement eligibility across the healthcare industry.
Operators in the healthcare sector should audit their reliance on Wuxi Apptec for critical research or manufacturing services. Review existing vendor contracts to identify potential service disruptions should the 1260H designation remain in effect or trigger additional Biosecure Act restrictions.
The takeaway
The firm’s effort to clear its military designation highlights the operational risk of relying on high-profile global vendors currently under federal scrutiny. Closely monitor the court proceedings in the District of Columbia as a signal for whether the firm will maintain its eligibility for federal contracts.
What happens next
Discovery and potential trial proceedings will occur throughout the remainder of 2026, leading up to the December 2026 deadline for the initial Biosecure biotechnology companies of concern list.
Further reading
For additional context on the evolving regulatory environment for medical providers, review our Healthcare section.
Source note: This article includes information reported by Bio World.
Live Poll
Do you trust the federal government's current process for blacklisting foreign companies as military threats?
